{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:28:35Z","timestamp":1788881315173,"version":"build-2803163510"},"reference-count":50,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although accumulating evidence strongly suggests that aplastic anemia (AA) is a T cell-mediated autoimmune disease, no target antigens have yet been described for AA. In autoimmune diseases, target autoantigens frequently induce not only cellular T-cell responses but also humoral B-cell responses. We hypothesized that the presence of antigen-specific autoantibodies could be used as a \u201csurrogate marker\u201d for the identification of target T-cell autoantigens in AA patients. We screened a human fetal liver library for serologic reactivity against hematopoietic stem\/progenitor cell antigens and isolated 32 genes. In 7 of 18 AA patients, an immunoglobulin G (IgG) antibody response was detected to one of the genes, kinectin, which is expressed in all hematopoietic cell lineages tested including CD34+ cells. No response to kinectin was detected in healthy volunteers, multiply transfused non-AA patients, or patients with other autoimmune diseases. Epitope mapping of IgG autoantibodies against kinectin revealed that the responses to several of the epitopes were shared by different AA patients. Moreover, CD8+ cytotoxic T cells raised against kinectin-derived peptides suppressed the colony formation of granulocyte macrophage colony-forming units (CFU-GMs) in an HLA class I-restricted fashion. These results suggest that kinectin may be a candidate autoantigen that is involved in the pathophysiology of AA. (Blood. 2003;102:4567-4575)<\/jats:p>","DOI":"10.1182\/blood-2002-11-3409","type":"journal-article","created":{"date-parts":[[2003,9,2]],"date-time":"2003-09-02T00:41:59Z","timestamp":1062463319000},"page":"4567-4575","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":93,"title":["Autoantibodies frequently detected in patients with aplastic anemia"],"prefix":"10.1182","volume":"102","author":[{"given":"Naoto","family":"Hirano","sequence":"first","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Maecker","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim L.","family":"Schultze","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Schur","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kojima","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C.","family":"Guinan","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Nadler","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA; Laboratory of Molecular Immunology, Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; and Department of Pediatrics, Nagoya University, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300022259300_REF1","unstructured":"Mathe G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Transplant Proc. 1971;3: 325-332."},{"key":"2020021300022259300_REF2","doi-asserted-by":"crossref","unstructured":"Young NS. Acquired aplastic anemia. JAMA. 1999;282: 271-278.","DOI":"10.1001\/jama.282.3.271"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Maciejewski JP, Risitano A, Kook H, Zeng W, Chen G, Young NS. Immune pathophysiology of aplastic anemia. Int J Hematol. 2002;76(suppl 1): 207-214.","DOI":"10.1007\/BF03165246"},{"key":"2020021300022259300_REF4","doi-asserted-by":"crossref","unstructured":"Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136: 534-546.","DOI":"10.7326\/0003-4819-136-7-200204020-00011"},{"key":"2020021300022259300_REF5","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995;85: 1348-1353.","DOI":"10.1182\/blood.V85.5.1348.bloodjournal8551348"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85: 3058-3065.","DOI":"10.1182\/blood.V85.11.3058.bloodjournal85113058"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Brodsky RA. High-dose cyclophosphamide for aplastic anemia and autoimmunity. Curr Opin Oncol. 2002;14: 143-146.","DOI":"10.1097\/00001622-200203000-00001"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol. 2002;75: 129-140.","DOI":"10.1007\/BF02982017"},{"key":"2020021300022259300_REF9","doi-asserted-by":"crossref","unstructured":"Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289: 1130-1135.","DOI":"10.1001\/jama.289.9.1130"},{"key":"2020021300022259300_REF10","doi-asserted-by":"crossref","unstructured":"Kagan WA, Ascensao JA, Pahwa RN, et al. Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesis. Proc Natl Acad Sci U S A. 1976;73: 2890-2894.","DOI":"10.1073\/pnas.73.8.2890"},{"key":"2020021300022259300_REF11","doi-asserted-by":"crossref","unstructured":"Hoffman R, Zanjani ED, Lutton JD, Zalusky R, Wasserman LR. Suppression of erythroid-colony formation by lymphocytes from patients with aplastic anemia. N Engl J Med. 1977;296: 10-13.","DOI":"10.1056\/NEJM197701062960103"},{"key":"2020021300022259300_REF12","doi-asserted-by":"crossref","unstructured":"Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A. 1985;82: 188-192.","DOI":"10.1073\/pnas.82.1.188"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Hinterberger W, Adolf G, Aichinger G, et al. Further evidence for lymphokine overproduction in severe aplastic anemia [see comments]. Blood. 1988;72: 266-272.","DOI":"10.1182\/blood.V72.1.266.266"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol. 2001;115: 1023-1031.","DOI":"10.1046\/j.1365-2141.2001.03212.x"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Nakao S, Yamaguchi M, Shiobara S, et al. Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood. 1992;79: 2532-2535.","DOI":"10.1182\/blood.V79.10.2532.bloodjournal79102532"},{"key":"2020021300022259300_REF16","doi-asserted-by":"crossref","unstructured":"Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100: 1185-1191.","DOI":"10.1182\/blood-2002-01-0035"},{"key":"2020021300022259300_REF17","doi-asserted-by":"crossref","unstructured":"Zoumbos NC, Gascon P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985;312: 257-265.","DOI":"10.1056\/NEJM198501313120501"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Herrmann F, Griffin JD, Meuer SG, Meyer zum Buschenfelde KH. Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis. J Immunol. 1986;136: 1629-1634.","DOI":"10.4049\/jimmunol.136.5.1629"},{"key":"2020021300022259300_REF19","unstructured":"Maciejewski JP, Hibbs JR, Anderson S, Katevas P, Young NS. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol. 1994;22: 1102-1110."},{"key":"2020021300022259300_REF20","doi-asserted-by":"crossref","unstructured":"Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci U S A. 1996;93: 2253-2256.","DOI":"10.1073\/pnas.93.6.2253"},{"key":"2020021300022259300_REF21","doi-asserted-by":"crossref","unstructured":"Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res. 1997;16: 313-339.","DOI":"10.1007\/BF02786397"},{"key":"2020021300022259300_REF22","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Podesta M, Mingari MC, Moretta L, Van Lint MT, Marmont A. Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes. J Immunol. 1980;125: 1449-1453.","DOI":"10.4049\/jimmunol.125.4.1449"},{"key":"2020021300022259300_REF23","doi-asserted-by":"crossref","unstructured":"Nakao S, Harada M, Kondo K, et al. Effect of activated lymphocytes on the regulation of hematopoiesis: suppression of in vitro granulopoiesis by OKT8+Ia+T cells induced by alloantigen stimulation. J Immunol. 1984;132: 160-164.","DOI":"10.4049\/jimmunol.132.1.160"},{"key":"2020021300022259300_REF24","doi-asserted-by":"crossref","unstructured":"Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood. 1997;89: 3691-3699.","DOI":"10.1182\/blood.V89.10.3691"},{"key":"2020021300022259300_REF25","doi-asserted-by":"crossref","unstructured":"Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47: 9-17.","DOI":"10.1002\/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I"},{"key":"2020021300022259300_REF26","doi-asserted-by":"crossref","unstructured":"Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995;92: 11810-11813.","DOI":"10.1073\/pnas.92.25.11810"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol. 1997;9: 709-716.","DOI":"10.1016\/S0952-7915(97)80053-2"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Old LJ, Chen YT. New paths in human cancer serology [comment]. J Exp Med. 1998;187: 1163-1167.","DOI":"10.1084\/jem.187.8.1163"},{"key":"2020021300022259300_REF29","doi-asserted-by":"crossref","unstructured":"Tureci O, Sahin U, Zwick C, Neumann F, Pfreundschuh M. Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma. 1999;18: 23-28.","DOI":"10.1089\/hyb.1999.18.23"},{"key":"2020021300022259300_REF30","doi-asserted-by":"crossref","unstructured":"Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187: 265-270.","DOI":"10.1084\/jem.187.2.265"},{"key":"2020021300022259300_REF31","doi-asserted-by":"crossref","unstructured":"Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000;191: 625-630.","DOI":"10.1084\/jem.191.4.625"},{"key":"2020021300022259300_REF32","doi-asserted-by":"crossref","unstructured":"Hirano N, Shibasaki F, Kato H, et al. Molecular cloning and characterization of a cDNA for bovine phospholipase C-alpha: proposal of redesignation of phospholipase C-alpha. Biochem Biophys Res Commun. 1994;204: 375-382.","DOI":"10.1006\/bbrc.1994.2469"},{"key":"2020021300022259300_REF33","doi-asserted-by":"crossref","unstructured":"Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152: 163-175.","DOI":"10.4049\/jimmunol.152.1.163"},{"key":"2020021300022259300_REF34","doi-asserted-by":"crossref","unstructured":"Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10: 673-679.","DOI":"10.1016\/S1074-7613(00)80066-7"},{"key":"2020021300022259300_REF35","doi-asserted-by":"crossref","unstructured":"Gubin AN, Njoroge JM, Bouffard GG, Miller JL. Gene expression in proliferating human erythroid cells. Genomics. 1999;59: 168-177.","DOI":"10.1006\/geno.1999.5855"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Lee S, Zhou G, Clark T, Chen J, Rowley JD, Wang SM. The pattern of gene expression in human CD15+ myeloid progenitor cells. Proc Natl Acad Sci U S A. 2001;98: 3340-3345.","DOI":"10.1073\/pnas.051013798"},{"key":"2020021300022259300_REF37","doi-asserted-by":"crossref","unstructured":"Hashimoto S, Nagai S, Sese J, et al. Gene expression profile in human leukocytes. Blood. 2003;101: 3509-3513.","DOI":"10.1182\/blood-2002-06-1866"},{"key":"2020021300022259300_REF38","doi-asserted-by":"crossref","unstructured":"Mao M, Fu G, Wu JS, et al. Identification of genes expressed in human CD34(+) hematopoietic stem\/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning. Proc Natl Acad Sci U S A. 1998;95: 8175-8180.","DOI":"10.1073\/pnas.95.14.8175"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Gomes I, Sharma TT, Mahmud N, et al. Highly abundant genes in the transcriptosome of human and baboon CD34 antigen-positive bone marrow cells. Blood. 2001;98: 93-99.","DOI":"10.1182\/blood.V98.1.93"},{"key":"2020021300022259300_","doi-asserted-by":"crossref","unstructured":"Zhou G, Chen J, Lee S, Clark T, Rowley JD, Wang SM. The pattern of gene expression in human CD34(+) stem\/progenitor cells. Proc Natl Acad Sci U S A. 2001;98: 13966-13971.","DOI":"10.1073\/pnas.241526198"},{"key":"2020021300022259300_REF41","doi-asserted-by":"crossref","unstructured":"Steidl U, Kronenwett R, Rohr UP, et al. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood. 2002;99: 2037-2044.","DOI":"10.1182\/blood.V99.6.2037"},{"key":"2020021300022259300_REF42","doi-asserted-by":"crossref","unstructured":"Toyoshima I, Yu H, Steuer ER, Sheetz MP. Kinectin, a major kinesin-binding protein on ER. J Cell Biol. 1992;118: 1121-1131.","DOI":"10.1083\/jcb.118.5.1121"},{"key":"2020021300022259300_REF43","doi-asserted-by":"crossref","unstructured":"Coppel RL, Gershwin ME. Primary biliary cirrhosis: the molecule and the mimic. Immunol Rev. 1995;144: 17-49.","DOI":"10.1111\/j.1600-065X.1995.tb00064.x"},{"key":"2020021300022259300_REF44","doi-asserted-by":"crossref","unstructured":"Warren KG, Catz I, Steinman L. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features. Proc Natl Acad Sci U S A. 1995;92: 11061-11065.","DOI":"10.1073\/pnas.92.24.11061"},{"key":"2020021300022259300_REF45","doi-asserted-by":"crossref","unstructured":"Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336: 1365-1372.","DOI":"10.1056\/NEJM199705083361906"},{"key":"2020021300022259300_REF46","doi-asserted-by":"crossref","unstructured":"Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Hepatitis-associated aplastic anemia [see comments]. N Engl J Med. 1997;336: 1059-1064.","DOI":"10.1056\/NEJM199704103361504"},{"key":"2020021300022259300_REF47","doi-asserted-by":"crossref","unstructured":"Wang W, Meadows LR, den Haan JM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 1995;269: 1588-1590.","DOI":"10.1126\/science.7667640"},{"key":"2020021300022259300_REF48","doi-asserted-by":"crossref","unstructured":"Meadows L, Wang W, den Haan JM, et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 1997;6: 273-281.","DOI":"10.1016\/S1074-7613(00)80330-1"},{"key":"2020021300022259300_REF49","doi-asserted-by":"crossref","unstructured":"Vogt MH, Goulmy E, Kloosterboer FM, et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood. 2000;96: 3126-3132.","DOI":"10.1182\/blood.V96.9.3126"},{"key":"2020021300022259300_REF50","doi-asserted-by":"crossref","unstructured":"Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol. 2000;164: 2807-2814.","DOI":"10.4049\/jimmunol.164.5.2807"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4567\/1693457\/h82403004567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4567\/1693457\/h82403004567.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T21:10:05Z","timestamp":1682543405000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/13\/4567\/17446\/Autoantibodies-frequently-detected-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,15]]},"references-count":50,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-11-3409","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,15]]}}}